Related Experiment Videos
Interleukin-1 receptor antagonist expression in sarcoidosis
M W Rolfe1, T J Standiford, S L Kunkel
1University of Michigan Medical Center, Department of Internal Medicine, Ann Arbor 48109-0360.
The American Review of Respiratory Disease
|November 1, 1993
Summary
Interleukin-1 receptor antagonist (IRAP) is expressed in sarcoidosis granulomas, suggesting it modulates inflammation. This finding offers insights into sarcoidosis immunopathogenesis and potential therapeutic targets.
Area of Science:
- Immunology
- Pulmonology
- Pathology
Background:
- Sarcoidosis is a systemic granulomatous disease primarily affecting the lungs.
- The exact cause of sarcoidosis remains unknown, but cytokines like Interleukin-1 beta (IL-1) are implicated.
- Despite significant inflammation, sarcoidosis often resolves spontaneously.
Purpose of the Study:
- To investigate the role of Interleukin-1 receptor antagonist (IRAP) in sarcoidosis.
- To determine if IRAP expression is altered in sarcoidosis patients.
- To explore IRAP's potential as an in vivo immunomodulator in sarcoidosis.
Main Methods:
- Collected bronchoalveolar lavage (BAL) fluid cells and cell-free fluid from normal subjects and sarcoidosis patients.
- Detected IRAP mRNA and antigen expression in BAL samples.
- Performed immunolocalization of IRAP within lung tissue.
Main Results:
- Constitutive expression of IRAP mRNA and antigen was observed in both normal and sarcoidosis subjects.
- IRAP was significantly localized to sarcoid granulomas compared to normal lung interstitium.
- IRAP expression appears compartmentalized within granulomas in sarcoidosis.
Conclusions:
- IRAP is expressed within sarcoid granulomas.
- IRAP may function as a key in vivo immunomodulator of granulomatous inflammation in sarcoidosis.
- These findings suggest IRAP's involvement in sarcoidosis pathogenesis.